Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Videos|December 25, 2017
Controlling C. difficile in Hospitals: It Takes a Team
Author(s)Contagion® Editorial Staff
Michael Edmond, MD, MPH, MPA, stresses that a collaborative effort is needed to control C. difficile in hospitals.
Advertisement
Michael Edmond, MD, MPH, MPA, chief quality officer at the University of Iowa Hospitals & Clinics, stresses that a collaborative effort is needed to control C. difficile in hospitals.
Interview Transcript (modified slightly for readability):
“For an infection like Clostridium difficile, it’s really multifactorial; it has to do with hand hygiene; it’s impacted by your environmental hygiene; it’s particularly impacted by the use of antibiotics in your hospital. I think that there needs to be a very tight relationship between the infection control program, the antibiotic stewardship program, your Environmental Services—all of these groups play a role in controlling a pathogen like C. diff.”
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
2
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
3
IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections
4
ID Week Highlights Part 1
5